tbuckley/cabot-search huggingface dataset:
483. Phenotypic Correction of Von Willebrand Disease Type 3 Blood-Derived Endothelial Cells with Lentiviral Vectors Expressing Von Willebrand Factor
Authors: Simon F. DeMeyer, Karen Van hoorelbeke, Marinee K. Chuah, Inge Pareyn, Veerle Gilijns, Robert P. Hebbel, Désiré Collen, Thierry Vandendriessche
Journal: Molecular Therapy (2006)
Oral contraceptives and thromboembolic disease. I. Prospective and retrospective studies
Authors: V. A. Drill
Journal: JAMA (1972)

The average normal incidence of superficial and deep-vein thromboembolic disease in women of childbearing age is 2.2 cases per 1,000 women per year. The incidence of this disease is not increased during pregnancy, when estrogen secretion is increased, or when oral contraceptives are employed. In over 80,000 women receiving oral contraceptives for more than 1,000,000 cycles the incidence of superficial and deep-vein thromboembolic disease is 0.97 cases per 1,000 women per year. Retrospective survey studies have provided the hypothesis of increased risk in women taking oral contraceptives, but this hypothesis is not confirmed by the large volume of prospective data. Available data do not demonstrate that women with a history of thromboembolic disease are more susceptible to a recurrence when using oral contraceptives, and women developing thrombophlebitis have recovered uneventfully while continuing to use oral contraceptives.
Results of Combined Hormone Therapy in Advanced Breast Cancer
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clearance of Inhaled Ceramic Fibers from Rat Lungs
Authors: H. Yamato, I. Tanaka, T. Higashi, M. Kido
Journal: Environmental Health Perspectives (1994)

Deposition, clearance, retention, and durability of inhaled particles in lungs are important factors for induction of pulmonary fibrosis or lung cancer.To study the deposition and clearance of aluminium silicate ceramic fibers from the lung, male Wistar rats were exposed to ceramic fibers, with a mass median aerodynamic diameter (MMAD) of 3.7 pm, for 6 hr/day, 5 days/week for 2 weeks.The average exposure concentration was 27.2 mg/m3 (SD 9.0).The rats were killed at 1 day, 1 month, 3 months, and 6 months after the end of exposure, and the fiber numbers and dimen- sions were measured with a scanning electron microscope.No significant difference in length of residual ceramic fibers in the lungs was found among the groups.The geometric mean diameter and number of ceramic fibers, however, decreased according to the clearance period.These find- ings suggest that the fibers were dissolved at their surface.
Cardiac toxicity 4 to 20 years after completing anthracycline therapy
Authors: L. J. Steinherz
Journal: JAMA (1991)

<h3>Objective.</h3> —To assess the cardiac status of long-term survivors of pediatric malignancies who received chemotherapy, including anthracyclines. <h3>Design and Method.</h3> —Patients were evaluated by echocardiogram from 4 to 20 years (median, 7 years) after completion of anthracyclines, with prospective and retrospective analysis. <h3>Patients.</h3> —The consecutive sample of 201 patients had received a total anthracycline dose of 200 to 1275 mg/m<sup>2</sup>(median, 450 mg/m2), and 51 patients had mediastinal radiotherapy. <h3>Main Outcome Measures.</h3> —The overall incidence and severity of abnormal systolic cardiac function were determined for the entire cohort. Risk factors of total anthracycline dose, mediastinal radiotherapy, age during treatment, and length of follow-up were examined. <h3>Results.</h3> —Twenty-three percent (47/201) of the cohort had abnormal cardiac function on noninvasive testing at long-term follow-up. Correlation between total cumulative dose, length of follow-up, and mediastinal irradiation with incidence of abnormalities was significant. Fifty-six patients were followed up for 10 years or more (median, 12 years), with a median anthracycline dose of 495 mg/m<sup>2</sup>, Thirty-eight percent (21/56) of these patients, compared with 18% (26/145) of patients evaluated after less than 10 years, had abnormal findings. Sixty-three percent of patients followed up for 10 years or more after receiving 500 mg/m<sup>2</sup>or more of anthracyclines had abnormal findings. Nine of 201 patients had late symptoms, including cardiac failure and dysrhythmia, and three patients died suddenly. Microscopic examination of the myocardium on biopsy and autopsy revealed fibrosis. <h3>Conclusion.</h3> —The 23% incidence of late cardiac abnormalities warrants continued evaluation of patients after anthracyclines to guide patient care and the design of future chemotherapeutic protocols. (JAMA. 1991;266:1672-1677)
THE DISCOVERY OF THE ANESTHETIC PROPERTIES OF COCAIN
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Collective Guilt
Authors: Gustav A. Uhlich
Journal: JAMA (1991)

<h3>To the Editor. —</h3> It is a sobering experience to read Dr Curfman's<sup>1</sup>story "Stein-Bockenheim." Lifelong exposure to anti-Germanism, it appears, has claimed another innocent victim and left Dr Curfman with the impression that much publicized German war crimes are more criminal than less publicized non-German war crimes. Even a cursory review of world history amply demonstrates the universal human potential for doing evil. When, where, and to what extent this potential raises its ugly head seems to depend on circumstances quite unrelated to the particular nationality, religion, or race of the perpetrator. Pointing fingers and wailing over imaginary misdeeds attributed to a distant relative in a foreign land some 50 years ago will do little to reduce the sum total of evil on this earth. Responsible personal conduct, here and now, offers itself as a promising option to all individuals of good will.
Proceedings of the Annual Congress on Medical Education.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manual of Specifications for the Purchase of Hospital Supplies and Equipment
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ectopic Pregnancy—United States, 1984 and 1985
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EGYPT
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients
Authors: J Burggraaf, R G J Westendorp, J C C M in‘t Veen, R C Schoemaker, P J Sterk, A F Cohen, G J Blauw
Journal: Thorax (2001)

BACKGROUND Beta-2 adrenoceptor agonists have been associated with sudden death in asthma patients but the cause and underlying mechanism are unclear. Animal experiments indicate that the combination of hypoxia and β 2 agonists may result in detrimental cardiovascular effects. A study was undertaken to investigate the effect of hypoxia on the systemic vascular effects of salbutamol in patients with asthma who are hypoxic by assessing forearm blood flow (FBF) as a measure of peripheral vasodilatation. METHODS Eight men with mild asthma underwent the following treatments: normoxia + placebo (NP), normoxia + salbutamol (NS), hypoxia + placebo (HP), and hypoxia + salbutamol (HS). The period of mask breathing started at t=0 minutes, lasted for 60 minutes, and at 30 minutes 800 μg salbutamol was inhaled. The experiment was completed 30 minutes after the inhalation (t=60 minutes). For the hypoxia treatment the Sp o 2 level was 82%. Differences between treatments were sought using factorial ANOVA on percentage change from the pretreatment value. RESULTS There were no significant differences in blood pressure and potassium levels between the treatments. After 60 minutes the increase in FBF was 13% (95% CI –12 to 39) more for HP treatment than for NP, 21% (95% CI –5 to 46) more for NS than for NP, and 32% (95% CI 7 to 58) more for HS than for HP (p=0.016). The inhalation of salbutamol during hypoxia resulted in a significant increase in FBF of 45% (95% CI 20 to 71) compared with NP (p=0.001). CONCLUSION Patients with asthma who are hypoxic and inhale β 2 agonists have serious systemic vascular side effects which may be an additional explanation for the association between asthma treatment and sudden death.
Hand-Book of Physiology.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prolonged hematopoietic reconstitution in patients failing previous peripheral blood stem cell collection, transplanted with adequate number of the CD34 cells obtained during bone marrow harvest
Authors: P. Mensah, W. Jurczak, B. Piatkowska - Jakubas, Z. Walter, D. Hawrylecka, A. B. Skotnicki
Journal: Journal of Clinical Oncology (2004)

6641
Disparate Mechanisms of Antifolate Resistance Provoked by Methotrexate and Its Metabolite 7-Hydroxymethotrexate in Leukemia Cells: Implications for Efficacy of Methotrexate Therapy.
Authors: Freidoun Albertioni, Gerrit Jansen, Kambiz Fotoohi, Yehuda G. Assaraf, Lilah Rothem, Michal Stark, Letje Kathmann, Jacek Gregorczyk, Godefridus J. Peters
Journal: Blood (2004)
Efficacy and safety of an acetyl CoA carboxylase inhibitor are improved in combination with PPAR agonists in a dyslipidemic rat model
Authors: Archana Vijayakumar, Isabel Olson, Ting Wang, David Hollenback, Maria Toteva, James Trevaskis, David Breckenridge, Jamie Bates
Journal: Journal of Hepatology (2020)
THE ACTION OF SALICYLATES ON THE URINARY TRACT.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Salicylate Intoxication
Authors: John B. Hill
Journal: New England Journal of Medicine (1973)

SINCE others have discussed this complex subject,1 2 3 the present communication will focus on two aspects bearing directly on any rational therapeutic approach — namely, the vulnerable organ and how to protect it.What kills the patient who has ingested a lethal dose of salicylate? Though the answer to this question is not known with certainty, there is evidence that many patients who die do so with signs and symptoms suggesting primary Central-nervous-system dysfunction. Data from animal experiments supporting this concept are presented in Figure 1. Varying doses and means of administration of salicylate were used to produce a lethal effect in . . .
Abstract LB-041: Targeting AKT2 and ERK decline the drug/radiation resistance in neuroblastoma
Authors: Kwang Woon Kim, Dai Chung, Jingbo Qiao, Julia Kim, Camille Poewers, Hernan Correa, Kyungho Park, Sora Lee
Journal: Cancer Research (2019)

Abstract Introduction: Neuroblastoma is highly heterogeneous, containing cancer cells with very different molecular characteristics. Activation of distinct signal transduction pathways can induce neuroblastoma cells to transform cells with neuronal, chromaffin, or schwannian phenotypes, further supporting the existence of cancer stem cells. We previously demonstrated that AKT2 plays critical roles in regulation of neuroblastoma tumorigenesis. Here we hypotheize that targeting AKT2 would block the signal transduction pathways enhanced in drug/radiation resistant neuroblastoma cancer stem cells. Methods: We generated cisplatin (CDDP) resistant and radiation (Rad) resistant neuroblastoma cells under the treatment or irradiation with a concentration of IC 50 of CDDP and 137Cs irradiator respectively. Cell viability was assessed with CCK-8 kit daily. Extreme limiting dilution analysis (ELDA) was performed for quantification of tumor sphere formation. Immunoblotting detected the expression of stem cell markers CD133, Sox2, ALDH, ALDH, Nestin, Oct4 and Nanog, as well as survival signaling pathway key molecules AKT2, MAPK and P38 MAPK. Results: We founded that two important cell proliferation and survival signaling pathways mTOR, downstream of AKT2 and MAPK enhanced in CDDP-resistant and Rad-resistant neuroblastoma cells. Blocking these two pathways with chemical inhibitors, CCT128930, AKT2 selective inhibitor and PD98059, MEK inhibitor decreased cell proliferation, angiogenesis, cell migration and soft agar conoly growth in these resistant cells. We further demonstrated that these resistant cells showed higher capacity of sphere-forming with increased expression of stem cell markers CD133, Sox2, ALDH, ALDH, Nestin, Oct4 and Nanog. Improtantly, the sphere formation of these resistant cells is sensitive to the inhibitors of AKT2 and MAPK. Conclusion: Our results suggest that selected CDDP-resistant and radiation-resistant neuroblastoma cells might serve as an useful tool to improve understanding of the molecular mechanisms of therapeutic resistance and develop more effective novel treatment strategies, and further to reaching better clinical outcomes of patients with neuroblastoma. Citation Format: Kwang Woon Kim, Dai Chung, Jingbo Qiao, Julia Kim, Camille Poewers, Hernan Correa, Kyungho Park, Sora Lee. Targeting AKT2 and ERK decline the drug/radiation resistance in neuroblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-041.
Telephone consultations
Authors: J. Car
Journal: BMJ (2003)

<h3>Abstract</h3> In immunocompetent subjects, the effectiveness of SARS-CoV-2 vaccines against the delta variant appears three- to five-fold lower than that observed against the alpha variant. Additionally, three doses of SARS-CoV-2 mRNA-based vaccines might be unable to elicit a sufficient immune response against any variant in immunocompromised kidney transplant recipients. This study describes the kinetics of the neutralizing antibody (NAbs) response against the delta strain before and after a fourth dose of a mRNA vaccine in 67 kidney transplant recipients who had experienced a weak antibody response after three doses. While only 16% of patients harbored NAbs against the delta strain prior to the fourth injection – this percentage raised to 66% afterwards. We also found that, after the fourth dose, the NAbs titer increased significantly (p=0.0001) from &lt;7.5 (IQR : &lt;7.5−15.1) to 47.1 (IQR &lt;7.5−284.2). Collectively, our data indicate that a fourth dose of the mRNA-1273 vaccine in kidney transplant recipients with a weak antibody response after three previous doses improves serum neutralization against the delta variant.